$5.29
1.34% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US56600D1072
Symbol
MRVI

Maravai LifeSciences Target price 2024 - Analyst rating & recommendation

Maravai LifeSciences Classifications & Recommendation:

Buy
57%
Hold
43%

Maravai LifeSciences Price Target

Target Price $9.41
Price $5.29
Potential
Number of Estimates 11
11 Analysts have issued a price target Maravai LifeSciences 2025 . The average Maravai LifeSciences target price is $9.41. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 8 Analysts recommend Maravai LifeSciences to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Maravai LifeSciences stock has an average upside potential 2025 of . Most analysts recommend the Maravai LifeSciences stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 288.95 259.45
67.28% 10.21%
EBITDA Margin 15.43% 16.75%
78.16% 8.57%
Net Margin -44.10% -31.97%
264.69% 27.51%

14 Analysts have issued a sales forecast Maravai LifeSciences 2024 . The average Maravai LifeSciences sales estimate is

$259m
Unlock
. This is
6.31% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$263m 5.03%
Unlock
, the lowest is
$255m 7.92%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $289m 67.28%
2024
$259m 10.21%
Unlock
2025
$268m 3.41%
Unlock
2026
$302m 12.45%
Unlock
2027
$324m 7.23%
Unlock
2028
$364m 12.64%
Unlock

14 Analysts have issued an Maravai LifeSciences EBITDA forecast 2024. The average Maravai LifeSciences EBITDA estimate is

$43.5m
Unlock
. This is
206.74% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$46.0m 224.63%
Unlock
, the lowest is
$41.0m 189.34%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $44.6m 92.85%
2024
$43.5m 2.50%
Unlock
2025
$51.2m 17.88%
Unlock
2026
$72.4m 41.34%
Unlock
2027
$78.7m 8.67%
Unlock
2028
$111m 40.91%
Unlock

EBITDA Margin

2023 15.43% 78.16%
2024
16.75% 8.57%
Unlock
2025
19.10% 14.03%
Unlock
2026
24.00% 25.65%
Unlock
2027
24.33% 1.38%
Unlock
2028
30.43% 25.07%
Unlock

6 Maravai LifeSciences Analysts have issued a net profit forecast 2024. The average Maravai LifeSciences net profit estimate is

$-83.0m
Unlock
. This is
64.49% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$58.8m 125.15%
Unlock
, the lowest is
$-150m 35.76%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-127m 153.89%
2024
$-83.0m 34.91%
Unlock
2025
$-26.5m 68.07%
Unlock
2026
$-8.8m 66.89%
Unlock

Net Margin

2023 -44.10% 264.69%
2024
-31.97% 27.51%
Unlock
2025
-9.87% 69.13%
Unlock
2026
-2.91% 70.52%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.90 -0.59
153.89% 34.44%
P/E negative
EV/Sales 3.86

6 Analysts have issued a Maravai LifeSciences forecast for earnings per share. The average Maravai LifeSciences <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.59
Unlock
. This is
64.24% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$0.41 124.85%
Unlock
, the lowest is
$-1.06 35.76%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.90 153.89%
2024
$-0.59 34.44%
Unlock
2025
$-0.19 67.80%
Unlock
2026
$-0.06 68.42%
Unlock

P/E ratio

Current -3.21 110.86%
2024
-9.03 181.31%
Unlock
2025
-28.28 213.18%
Unlock
2026
-85.43 202.09%
Unlock

Based on analysts' sales estimates for 2024, the Maravai LifeSciences stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.62 36.09%
2024
3.86 6.61%
Unlock
2025
3.73 3.30%
Unlock
2026
3.32 11.07%
Unlock
2027
3.10 6.74%
Unlock
2028
2.75 11.22%
Unlock

P/S ratio

Current 2.71 60.73%
2024
2.89 6.74%
Unlock
2025
2.80 3.30%
Unlock
2026
2.49 11.07%
Unlock
2027
2.32 6.74%
Unlock
2028
2.06 11.23%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today